Taxus Free: Angiotech Carves Out New $625 Million Subsidiary
This article was originally published in The Gray Sheet
Executive Summary
Combo product firm Angiotech Pharmaceuticals' creation of a new investor-supported subsidiary for its non-paclitaxel business could lead to an eventual spinoff of Angiotech Pharmaceutical Interventions, the firm announces July 7